Adenosine deaminase deficiency

Area of Science:

• Immunology
• Biochemistry
• Genetics

Background:

• Inherited adenosine deaminase (ADA) deficiency causes a spectrum of immune disorders, primarily Severe Combined Immunodeficiency (SCID).
• Pathology results from toxic substrate and metabolite accumulation (adenosine, deoxyadenosine, deoxy ATP) in lymphoid cells.
• These metabolites disrupt lymphoid proliferation and function through mechanisms like DNA damage and impaired synthesis.

Purpose of the Study:

• To define the clinical spectrum of ADA deficiency.
• To elucidate the molecular mechanisms underlying ADA deficiency-induced immunodeficiency.
• To review current and emerging treatment strategies for ADA deficiency.

Main Methods:

• Diagnosis involves enzyme assays in various cell types (erythrocytes, lymphocytes, fibroblasts).
• Genetic analysis of the ADA gene on chromosome 20.
• Review of treatment outcomes including bone-marrow transplantation, enzyme replacement, and gene therapy.

Main Results:

• ADA deficiency is a major cause of autosomal recessive SCID, with variable clinical severity.
• Molecular mechanisms involve chromosome breaks, inhibited ribonucleotide reductase, and inactivated SAH hydrolase.
• Gene mutations include single base pair substitutions, splicing defects, and deletions.
• Bone-marrow transplantation is the primary treatment; enzyme replacement and gene therapy are alternative/emerging options.

Conclusions:

• ADA deficiency presents a wide clinical spectrum, from severe SCID to milder immunodeficiencies.
• Understanding the molecular basis is crucial for diagnosis and treatment development.
• Gene therapy holds significant potential for long-term correction of ADA deficiency.